This refresh
Data-driven refresh June 4, 2026. Top 5 per bucket by live Bull Rankings score across a 5182-ticker universe covering every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (2538 passed the market-cap / liquidity screen). Fundamentals sourced from Yahoo Finance quoteSummary + quarterly FCF reconstruction; narrative authored by Groq (with Gemini and data-driven fallbacks). Intraday re-ranking from a top-30 per-bucket shortlist.
Growth — high-quality compounders
1. KGC — Kinross Gold Corporation · score 99
Gold · price $28.60 · 1Y $40.91 · 5Y $46.06 · 10Y $67.71
FCF $3.0b B · Rev +36.9% A · D/E 0.08 A- · P/E 12.2x A- · PEG 1.12 B+
Why now. Kinross Gold Corporation, a mid-cap gold miner, is currently trading at $28.60 with a 12.2 P/E ratio and a 36.9% revenue growth rate. The company's 36% profit margin and $3.0 billion in free cash flow indicate a strong financial position. With an analyst consensus 1-yr target of $40.91, the stock has potential for upside.
Moat. Kinross Gold Corporation's return on equity of 35.5% can be attributed to its ability to maintain a high profit margin in the gold mining sector. The company's diversified production and low debt-to-equity ratio of 0.08 contribute to its financial stability. As a precious-metals miner, Kinross benefits from the sector's inherent pricing power and low-cost production advantages.
Risk. The company's beta of 1.37 indicates a higher volatility compared to the market. Additionally, the debt-to-equity ratio, although currently low at 0.08, could increase if the company takes on more debt to finance its operations. The stock's valuation, with a PEG ratio of 1.12, may also be a concern if the growth rate slows down.
Horizon. 1-3 yr $40.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $46.06 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $67.71 if current growth sustains into durable earnings power.
2. FSM — Fortuna Mining Corp. · score 97
Gold · price $9.45 · 1Y $10.87 · 5Y $15.22 · 10Y $22.37
FCF $563m C+ · Rev +39.8% A · D/E 0.11 A- · P/E 8.7x A · PEG n/a
Why now. Fortuna Mining Corp., a growth-oriented gold mining company, is currently trading at a $9.45 price point with a 8.7 P/E ratio, indicating a relatively low valuation. The company has demonstrated a 39.8% revenue growth rate in the last fiscal year, driven by its diversified production geographies and efficient operations. With an analyst consensus target of $14, there is potential for significant upside.
Moat. Fortuna Mining Corp.'s durable competitive advantage stems from its 22% return on equity, which is driven by its 31.1% profit margin. This high margin is a result of the company's ability to maintain low production costs and its strategic positioning in the gold mining sector. Additionally, the company's 0.11 debt-to-equity ratio suggests a healthy balance sheet, allowing for further investment in growth initiatives.
Risk. The primary risks facing Fortuna Mining Corp. include its 2.09 beta, indicating a high level of volatility, and the potential for fluctuations in gold prices. Furthermore, the company's 39.8% revenue growth rate may be difficult to sustain, and any decline in growth could negatively impact the stock price. The company's reliance on a single analyst consensus target of $14 also introduces some uncertainty.
Horizon. 1-3 yr $10.87 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $15.22 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $22.37 if current growth sustains into durable earnings power.
3. PICS — PicS N.V. · score 97
Software - Infrastructure · price $9.16 · 1Y $21.14 · 5Y $14.75 · 10Y $21.69
FCF $166m C · Rev +65.0% A · D/E 0.13 B+ · P/E 5.2x A · PEG n/a
Why now. PicS N.V., a software infrastructure company, is currently trading at a $9.16 price with a 5.2 P/E ratio, indicating undervaluation. The company has a high revenue growth rate of 65%, driven by its strong position in the software infrastructure sector. With a $1.2b market cap and $166m in free cash flow, PicS N.V. has a solid financial foundation to support its growth.
Moat. PicS N.V.'s durable competitive advantage stems from its high 30.7% return on equity, which is driven by its 10% profit margin and efficient business model. The company's low 0.13 debt-to-equity ratio also provides a cost advantage, allowing it to invest in growth initiatives while maintaining a strong balance sheet. This advantage is further reinforced by the company's position in the software infrastructure sector, where scale and network effects can create significant barriers to entry.
Risk. Despite its strong fundamentals, PicS N.V. faces risks related to its high growth rate, which may be difficult to sustain. The company's 65% revenue growth rate may slow down, and its 5.2 P/E ratio may not provide a sufficient margin of safety if growth slows. Additionally, the company's reliance on a single sector may expose it to industry-specific risks, such as changes in technology or regulatory environments.
Horizon. 1-3 yr $21.14 (analyst consensus (n=9)) — fundamentals + valuation re-rating. 5 yr $14.75 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $21.69 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 96
Software - Infrastructure · price $11.77 · 1Y $17.35 · 5Y $18.96 · 10Y $27.86
FCF $374m C · Rev +46.6% A · D/E 0.20 B+ · P/E 18.4x A- · PEG n/a
Why now. DLocal Limited, a software infrastructure company, is poised for growth with a 46.6% revenue growth rate and a 15.8% profit margin. The current price of $11.77 and a P/E of 18.4 suggest a reasonable valuation. With an analyst consensus 1-yr target of $17.35, the company's growth prospects are driven by its strong financials and sector dynamics.
Moat. DLocal Limited's durable competitive advantage stems from its high 35% ROE, which is driven by its pricing power and cost advantages in the software infrastructure sector. The company's 2.9 PS ratio and $374m in free cash flow indicate a strong business model. Its debt-to-equity ratio of 0.2 also suggests a healthy balance sheet.
Risk. The company faces risks from its high 1.02 beta, which indicates volatility, and its dependence on growth, which may be impacted by sector dynamics. Additionally, the 0.2 debt-to-equity ratio, while healthy, may increase if the company takes on more debt to fuel growth. The $3.5b market cap also makes it vulnerable to market fluctuations.
Horizon. 1-3 yr $17.35 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $18.96 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $27.86 if current growth sustains into durable earnings power.
5. GPOR — Gulfport Energy Corporation · score 95
Oil & Gas E&P · price $171.06 · 1Y $242.00 · 5Y $275.49 · 10Y $404.96
FCF $362m C · Rev +42.5% A · D/E 0.46 B+ · P/E 5.6x A · PEG n/a
Why now. Gulfport Energy Corporation, an Oil & Gas E&P company, is currently trading at $171.06 with a 5.6 P/E ratio, indicating undervaluation. The company's 42.5% revenue growth rate and 42.1% profit margin suggest a strong growth trajectory. With an analyst consensus 1-yr target of $242, there is potential for significant upside.
Moat. Gulfport Energy's 34% ROE is driven by its ability to maintain a high profit margin in the Oil & Gas E&P sector. The company's 2.2 PS ratio and $362m in free cash flow also suggest a strong financial position. This is likely due to the company's focus on efficient operations and cost management, allowing it to maintain a competitive edge in the industry.
Risk. One of the main risks facing Gulfport Energy is its 0.46 debt-to-equity ratio, which could become a concern if interest rates rise. Additionally, the company's 0.46 beta indicates a relatively low level of volatility, but this could also mean that the stock is more sensitive to industry-wide fluctuations. The $3.1b market cap also makes the company vulnerable to potential market downturns.
Horizon. 1-3 yr $242.00 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $275.49 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $404.96 if current growth sustains into durable earnings power.
Value — quality at a discount
1. AU — AngloGold Ashanti plc · score 100
Gold · price $92.17 · 1Y $119.86 · 5Y $123.34 · 10Y $157.44
FCF $4.2b B · Rev +70.8% A · D/E 0.22 B+ · P/E 13.5x A- · PEG 0.78 A-
Why now. AngloGold Ashanti plc, a mid-cap gold miner, currently trades at $92.17 with a 13.5 P/E ratio, indicating statistical cheapness. The company has a 70.8% revenue growth rate and a 31.1% profit margin, driven by its diversified production geographies. With an analyst consensus 1-yr target of $119.86, the setup rewards patience as the company redirects its free cash flow into buybacks.
Moat. AngloGold Ashanti's 43% ROE is driven by its pricing power in the gold sector, resulting from its category leadership and diversified production geographies. The company's 0.22 debt-to-equity ratio and $4.2B free cash flow provide a cost advantage, allowing it to maintain its market position. Its mid-cap size and diversified production also contribute to its moat, making it a significant player in the gold sector.
Risk. The company faces risks from its 0.62 beta, indicating moderate volatility, and its 13.5 P/E ratio, which may be elevated. Additionally, the gold sector is subject to cyclical fluctuations, and AngloGold Ashanti's revenue growth may be impacted by changes in gold prices. The company's 0.22 debt-to-equity ratio, while relatively low, still poses a risk if interest rates rise or gold prices decline.
Horizon. 1-3 yr $119.86 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $123.34 at ~6% CAGR — dividend + buyback compounding. 10 yr $157.44 if the moat survives secular pressure.
2. INCY — Incyte Corporation · score 98
Biotechnology · price $101.24 · 1Y $107.96 · 5Y $135.48 · 10Y $172.93
FCF $1.4b C+ · Rev +21.2% A- · D/E 0.01 A · P/E 14.3x A- · PEG 0.36 A
Why now. Incyte Corporation, a biotechnology company, is undervalued given its 26.7% profit margin, $1.4b in free cash flow, and 21.2% revenue growth rate. With a current price of $101.24 and a P/E of 14.3, the stock has a low valuation multiple compared to its growth prospects. The analyst consensus 1-yr target of $107.96 suggests a potential upside, driven by the company's strong financials and growth trajectory.
Moat. Incyte's high return on equity of 30.8% is driven by its ability to maintain a high profit margin in the biotechnology sector. The company's low debt-to-equity ratio of 0.01 also provides financial flexibility, allowing it to invest in research and development and drive long-term growth. Additionally, the company's strong free cash flow generation enables it to reinvest in the business and return value to shareholders.
Risk. One of the key risks facing Incyte is the potential for revenue deceleration, given its high revenue growth rate of 21.2%. Additionally, the company's low beta of 0.8 may not fully capture the potential volatility of the biotechnology sector. Furthermore, the company's PEG ratio of 0.36 may indicate that the stock is undervalued, but it also highlights the potential for multiple compression if growth slows.
Horizon. 1-3 yr $107.96 (analyst consensus (n=24)) — multiple re-rating thesis requires a catalyst. 5 yr $135.48 at ~6% CAGR — dividend + buyback compounding. 10 yr $172.93 if the moat survives secular pressure.
3. PDD — PDD Holdings Inc. · score 98
Internet Retail · price $85.88 · 1Y $120.36 · 5Y $114.93 · 10Y $146.70
FCF $15.8b A- · Rev +9.7% B · D/E 0.01 A · P/E 9.0x A · PEG 0.82 B+
Why now. PDD Holdings Inc., an internet retail company, is undervalued given its $15.8b in free cash flow, 9.7% revenue growth rate, and 21.6% profit margin. The current price of $85.88 and P/E of 9 suggest statistical cheapness. With an analyst consensus 1-yr target of $120.36, there is potential for re-rating.
Moat. PDD's durable competitive advantage stems from its high return on equity of 25.4%, driven by its ability to generate significant free cash flow and maintain a low debt-to-equity ratio of 0.01. This allows the company to invest in its business and reward shareholders, creating a self-reinforcing cycle. The company's low beta of 0.03 also suggests a relatively stable business model.
Risk. The main risks facing PDD include the potential for revenue growth deceleration, given its current 9.7% growth rate, and the impact of changes in the internet retail sector. Additionally, the company's low P/E of 9 may not be sustainable if the company's growth rate slows or if the sector experiences a downturn. The low debt-to-equity ratio of 0.01 also means the company may not have the flexibility to take on debt to finance growth initiatives.
Horizon. 1-3 yr $120.36 (analyst consensus (n=33)) — multiple re-rating thesis requires a catalyst. 5 yr $114.93 at ~6% CAGR — dividend + buyback compounding. 10 yr $146.70 if the moat survives secular pressure.
4. ACN — Accenture plc · score 96
Information Technology Services · price $178.86 · 1Y $241.55 · 5Y $239.36 · 10Y $305.52
FCF $12.5b A- · Rev +7.4% B · D/E 0.25 B · P/E 14.6x A- · PEG 1.31 B
Why now. Accenture plc, a leader in Information Technology Services, is undervalued given its 10.6% profit margin, $12.5B in free cash flow, and 7.4% revenue growth rate. The company's current price of $178.86 and P/E of 14.6 suggest a re-rating catalyst could drive the stock towards the analyst consensus target of $241.55. With a debt-to-equity ratio of 0.25, Accenture has a solid balance sheet to support its growth initiatives.
Moat. Accenture's durable competitive advantage stems from its high return on equity of 24.8%, driven by its pricing power in the Information Technology Services sector. The company's ability to maintain a 10.6% profit margin and generate significant free cash flow demonstrates its cost advantages and efficiency. With a market capitalization of $110.1B, Accenture has the scale and resources to invest in its business and maintain its market position.
Risk. Accenture faces risks from its dependence on a few large clients, with a potential decline in revenue if these clients were to leave. The company's debt-to-equity ratio of 0.25 is relatively low, but an increase in debt could pose a risk to its financial health. Additionally, the Information Technology Services sector is highly competitive, and Accenture must continue to innovate and invest in its services to maintain its market position and grow its revenue.
Horizon. 1-3 yr $241.55 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $239.36 at ~6% CAGR — dividend + buyback compounding. 10 yr $305.52 if the moat survives secular pressure.
5. BZ — KANZHUN LIMITED · score 96
Internet Content & Information · price $14.24 · 1Y $21.19 · 5Y $19.06 · 10Y $24.32
FCF $682m C+ · Rev +12.4% B+ · D/E 0.01 A · P/E 13.4x B+ · PEG 0.18 A
Why now. KANZHUN LIMITED, operating in the Internet Content & Information sector, presents an attractive setup with a current price of $14.24, a P/E of 13.4, and a revenue growth rate of 12.4%. The company's profit margin of 40.1% and FCF of $682m further underscore its value proposition. As a value name, the statistical cheapness is evident, with a potential re-rating catalyst being the analyst consensus 1-yr target of $21.19.
Moat. KANZHUN LIMITED's durable competitive advantage is rooted in its ROE of 18.2%, which can be attributed to its pricing power and cost advantages in the Internet Content & Information sector. The company's low debt-to-equity ratio of 0.01 and high profit margin also contribute to its moat, allowing it to maintain a competitive edge in the market.
Risk. The primary risks facing KANZHUN LIMITED include its beta of 0.48, which, although relatively low, still poses some volatility risk. Additionally, the company's revenue growth rate of 12.4% may be impacted by sector-specific cycles, and its PEG ratio of 0.18 may indicate potential overvaluation. Furthermore, the analyst recommendation mean of 1.36 suggests a strong buy consensus, but also implies a potential for downward revision if the company fails to meet expectations.
Horizon. 1-3 yr $21.19 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $19.06 at ~6% CAGR — dividend + buyback compounding. 10 yr $24.32 if the moat survives secular pressure.
Speculative — asymmetric upside
1. WIX — Wix.com Ltd. · score 89
Software - Infrastructure · price $53.70 · 1Y $86.05 · 5Y $108.01 · 10Y $281.06
FCF $505m C+ · Rev +13.2% B+ · D/E n/a · P/S 1.1x A · PEG 0.13 A
Why now. Wix.com Ltd., a software infrastructure company, is currently trading at $53.70 with a 13.2% revenue growth rate and a 1.1 price-to-sales ratio, indicating a potential undervaluation. The company's $505m free cash flow and 0.13 PEG ratio suggest a promising growth trajectory. As a high-risk, high-reward investment, Wix's success hinges on its ability to maintain growth momentum and expand its customer base.
Moat. Wix's moat lies in its ability to generate significant free cash flow, with a $505m figure reported in the last period. The company's software infrastructure business model allows for high margins and scalability, enabling it to invest in growth initiatives and maintain its competitive position. With a 1.01 beta, Wix's stock price is relatively volatile, but its 1.1 price-to-sales ratio suggests a reasonable valuation.
Risk. Wix faces risks related to its high growth expectations, with a 13.2% revenue growth rate that may be challenging to sustain. The company's -2% profit margin and lack of profitability may also pose concerns. Additionally, the 1.01 beta indicates a relatively high level of stock price volatility, which may be a concern for investors seeking stable returns.
Horizon. 1-3 yr $86.05 (analyst consensus (n=19)) — catalyst-driven; binary events dominate. 5 yr $108.01 — requires the platform / technology to reach commercial scale. 10 yr $281.06 — return distribution heavily skewed.
2. BILL — BILL Holdings, Inc. · score 88
Software - Application · price $35.96 · 1Y $55.10 · 5Y $72.33 · 10Y $188.21
FCF $327m C · Rev +13.4% B+ · D/E 0.50 B · P/S 2.2x A- · PEG 0.38 A
Why now. BILL Holdings, Inc., a software application company, is currently trading at $35.96 with a 13.4% revenue growth rate and a 0.38 PEG ratio, indicating a high-risk, high-reward setup. The company's free cash flow of $327m and debt-to-equity ratio of 0.5 provide a glimpse into its financial health. With an analyst consensus 1-yr target of $55.10, the stock has potential for significant upside.
Moat. BILL's moat lies in its ability to generate $327m in free cash flow, which can be used to invest in growth initiatives or return value to shareholders. The company's 2.2 price-to-sales ratio and 0.38 PEG ratio suggest a relatively low valuation compared to its growth prospects. Additionally, BILL's 1.22 beta indicates a higher level of volatility, which can be a double-edged sword for investors.
Risk. The main risks facing BILL include its 0% profit margin, which indicates a lack of profitability, and its 1.22 beta, which suggests a higher level of volatility. Additionally, the company's 0.5 debt-to-equity ratio and 0% return on equity (ROE) raise concerns about its financial health and ability to generate returns for shareholders.
Horizon. 1-3 yr $55.10 (analyst consensus (n=21)) — catalyst-driven; binary events dominate. 5 yr $72.33 — requires the platform / technology to reach commercial scale. 10 yr $188.21 — return distribution heavily skewed.
3. CRC — California Resources Corporation · score 87
Oil & Gas E&P · price $61.00 · 1Y $82.45 · 5Y $122.69 · 10Y $319.26
FCF $778m C+ · Rev +15.1% B+ · D/E 0.47 B+ · P/S 1.6x B+ · PEG 0.29 A
Why now. California Resources Corporation, an Oil & Gas E&P company, is currently set up with a 15.1% revenue growth rate and a $778m free cash flow, positioning it for potential high-risk, high-reward returns. With an analyst consensus 1yr target of $82.45 and a peg ratio of 0.29, the company's growth prospects appear promising. As a spec name, CRC's binary setup relies on its ability to navigate the challenges of the oil and gas industry, where it sells its products to various end markets.
Moat. CRC's moat lies in its ability to generate $778m in free cash flow, which can be used to invest in its operations, pay off debt, or return value to shareholders. The company's profit margin of -13.4% and ROE of -14.4% are currently negative, but its debt-to-equity ratio of 0.47 suggests a relatively manageable debt burden. As an Oil & Gas E&P company, CRC's business model is subject to the economics of the sector, including fluctuations in commodity prices and regulatory environments.
Risk. CRC faces material risks, including a debt-to-equity ratio of 0.47, which, while manageable, still poses a risk to the company's financial health. Additionally, the company's beta of 0.96 indicates a relatively high level of market risk, and its negative profit margin and ROE suggest ongoing operational challenges. The oil and gas industry is also subject to regulatory risks, including potential changes to environmental regulations or tax policies, which could impact CRC's operations and profitability.
Horizon. 1-3 yr $82.45 (analyst consensus (n=11)) — catalyst-driven; binary events dominate. 5 yr $122.69 — requires the platform / technology to reach commercial scale. 10 yr $319.26 — return distribution heavily skewed.
4. BHC — Bausch Health Companies Inc. · score 85
Drug Manufacturers - Specialty & Generic · price $5.26 · 1Y $7.50 · 5Y $10.58 · 10Y $27.53
FCF $989m C+ · Rev +6.7% C+ · D/E n/a · P/S 0.2x A · PEG 0.01 A
Why now. Bausch Health Companies Inc., a specialty and generic drug manufacturer, is currently trading at $5.26 with a 6.7% revenue growth rate and a 0.2 price-to-sales ratio, indicating potential undervaluation. The company has a $989m free cash flow, which could be utilized to drive future growth. With an analyst consensus 1-year target of $7.50, there is a potential upside for investors.
Moat. Bausch Health's moat lies in its ability to generate significant free cash flow, with $989m in the trailing twelve months. This is a result of its business model, which focuses on specialty and generic drug manufacturing, allowing for diversification and reduced dependence on a single product. The company's 0.42 beta indicates a relatively low volatility, which could be attractive to investors seeking stable returns.
Risk. One of the primary risks facing Bausch Health is its -11.5% profit margin, which indicates a loss-making position. Additionally, the company's 0.01 PEG ratio may suggest that the stock is undervalued, but it also implies a high-risk, high-reward scenario. The 6 analyst consensus, with a mean recommendation of 2.89, indicates a 'hold' rating, which may reflect the uncertainty surrounding the company's future prospects.
Horizon. 1-3 yr $7.50 (analyst consensus (n=6)) — catalyst-driven; binary events dominate. 5 yr $10.58 — requires the platform / technology to reach commercial scale. 10 yr $27.53 — return distribution heavily skewed.
5. CNC — Centene Corporation · score 84
Healthcare Plans · price $62.70 · 1Y $60.06 · 5Y $126.11 · 10Y $328.16
FCF $7.1b B+ · Rev +19.4% B+ · D/E 0.76 C+ · P/S 0.2x A · PEG 1.15 B+
Why now. Centene Corporation, a mid-cap healthcare plans provider, is poised for growth driven by its 19.4% revenue growth rate and $7.1b in free cash flow. With a current price of $62.7, the company's valuation is supported by its 0.2 price-to-sales ratio. As a spec name, CNC's binary setup relies on its ability to navigate the high-risk, high-reward healthcare plans market, where it must balance 1.15 PEG ratio with a negative -3.6% profit margin.
Moat. Centene Corporation's moat is rooted in its ability to generate $7.1b in free cash flow, which can be used to invest in its business and maintain its market position. The company's 0.76 debt-to-equity ratio provides a degree of financial flexibility, allowing it to make strategic investments. Additionally, its 1.06 beta suggests a relatively stable stock price, which can help attract long-term investors.
Risk. Centene Corporation faces significant risks, including its negative -26% return on equity, which indicates a need for improved profitability. The company's -3.6% profit margin is a concern, and its ability to navigate the complex healthcare plans market will be crucial to its success. Additionally, the company's 1.15 PEG ratio suggests a relatively high valuation, which may be a risk if the company's growth rate slows.
Horizon. 1-3 yr $60.06 (analyst consensus (n=17)) — catalyst-driven; binary events dominate. 5 yr $126.11 — requires the platform / technology to reach commercial scale. 10 yr $328.16 — return distribution heavily skewed.
Methodology footnote
Every pick on this list comes out of the same seven-grade quantitative model applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades and adjustments produced the number. Not investment advice. See terms for full disclosures.